Post Profile






Novartis CAR-T therapy leads to durable response in lymphoma study

(Reuters) - Patients with an advanced form of an aggressive blood cancer who had initially responded to Novartis' new type of gene-modifying immunotherapy continued to respond at least six months after treatment, according to updated data released at a medical meeting on Sunday.
read more

share

Related Posts


'Unheard of' responses to bluebird CAR-T therapy seen in myeloma study

Health : Reuters: Health

(Reuters) - More than half of patients with advanced multiple myeloma who had run out of therapeutic options remained in complete remission after receiving bluebird bio Inc's experimental gene-modifying immunotherapy in a small, ear...

Phase 2 CAR-T study reports significant remission rates at 15-month follow up

Health : EurekAlert: Health

(University of Texas M. D. Anderson Cancer Center) A study involving the recently approved CD19-targeting chimeric antigen receptor (CAR) T cell therapy shows that 42 percent of patients with aggressive large B-cell lymphoma remaine...

Phase 2 CAR-T Study Reports Significant Remission Rates at 15-Month Follow Up

Health : Newswise Medical News

A study involving the recently approved CD19-targeting chimeric antigen receptor (CAR) T cell therapy shows that 42 percent of patients with aggressive large B-cell lymphoma remained in remission at 15 months following treatment wit...

Roche lymphoma drug drives high remission rate, longer survival: study

Health : Reuters: Health

(Reuters) - An experimental Roche Holding AG drug, added to standard therapy, led to a far higher rate of remission and helped patients with an advanced, aggressive blood cancer live significantly longer than the standard treatment ...

Gilead's new drug keeps 56 percent of lymphoma trial patients alive

Health : Reuters: Health

(Reuters) - More than half of trial patients with an advanced, aggressive form of blood cancer lived for at least a year after one-time treatment with Yescarta, a novel therapy sold by Gilead Sciences Inc, according to study results...

Comments


Copyright © 2016 Regator, LLC